@article{pmid37297934,

title = {Clinical Assessment of Judgment in Adults and the Elderly: Development and Validation of the Three Domains of Judgment Test-Clinical Version (3DJT-CV)},

author = {Simon-Pierre Bernard-Arevalo and Robert Jr Laforce and Olivier Khayat and Vital Bouchard and Marie-Andrée Bruneau and Sarah Brunelle and Stéphanie Caron and Laury Chamelian and Marise Chénard and Jean-François Côté and Gabrielle Crépeau-Gendron and Marie-Claire Doré and Marie-Pierre Fortin and Nadine Gagnon and Pierre R Gagnon and Chloé Giroux and Léonie Jean and Geneviève Létourneau and Émilie Marceau and Vincent Moreau and Michèle Morin and Christine Ouellet and Stéphane Poulin and Steve Radermaker and Katerine Rousseau and Catherine Touchette and Alexandre Dumais},

doi = {10.3390/jcm12113740},

issn = {2077-0383},

year  = {2023},

date = {2023-05-01},

journal = {J Clin Med},

volume = {12},

number = {11},

abstract = {(1) Background: This article discusses the first two phases of development and validation of the Three Domains of Judgment Test (3DJT). This computer-based tool, co-constructed with users and capable of being administered remotely, aims to assess the three main domains of judgment (practical, moral, and social) and learn from the psychometric weaknesses of tests currently used in clinical practice. (2) Method: First, we presented the 3DJT to experts in cognition, who evaluated the tool as a whole as well as the content validity, relevance, and acceptability of 72 scenarios. Second, an improved version was administered to 70 subjects without cognitive impairment to select scenarios with the best psychometric properties in order to build a future clinically short version of the test. (3) Results: Fifty-six scenarios were retained following expert evaluation. Results support the idea that the improved version has good internal consistency, and the concurrent validity primer shows that 3DJT is a good measure of judgment. Furthermore, the improved version was found to have a significant number of scenarios with good psychometric properties to prepare a clinical version of the test. (4) Conclusion: The 3DJT is an interesting alternative tool for assessing judgment. However, more studies are needed for its implementation in a clinical context.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid33282048,

title = {Validation of the Dépistage Cognitif de Québec in the Oldest Old},

author = {Amélie Gravel and Carol Hudon and Synthia Meilleur-Durand and Leila Sellami and David Bergeron and Audrey Paradis and Louis Verret and Marie-Pierre Fortin and Stéphane Poulin and Joël Macoir and Rémi W Bouchard and Robert Laforce},

doi = {10.5770/cgj.23.432},

issn = {1925-8348},

year  = {2020},

date = {2020-12-01},

journal = {Can Geriatr J},

volume = {23},

number = {4},

pages = {283--288},

abstract = {OBJECTIVE: We aimed to validate the  (DCQ; www.dcqtest.org), a new cognitive screening tool for atypical degenerative syndromes, in the oldest old.nnMETHODS: The DCQ was developed by expert behavioural neurologists and clinical neuropsychologists based on updated criteria for Alzheimer's disease, primary progressive aphasia, and behavioural variant frontotemporal dementia. It targets five relevant cognitive domains: Memory, Visuospatial, Executive, Language, and Behaviour. Validation was performed using a prospective community-based sample consisting of 53 healthy French-speaking Canadian volunteers aged between 80 and 94 years old. Normative data were derived from participants with no history of cognitive difficulties and a Montreal Cognitive Assessment (MoCA) score ≥ 24.nnRESULTS: The mean DCQ total score (out of 100) was 84.65 (SD = 6.33). Pearson's correlation coefficient showed a moderate, but significant, correlation ( = 0.36,  < .01) with the MoCA. Normative data shown in percentiles were stratified by age and education for DCQ total score and for each of the five cognitive domains.nnCONCLUSIONS: This study suggests that the DCQ is a valid cognitive screening test in the oldest old. It is proposed that the DCQ can help early identification of atypical degenerative syndromes.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid33207355,

title = {The Behavioral/Dysexecutive Variant of Alzheimer's Disease: A Case Series with Clinical, Neuropsychological, and FDG-PET Characterization},

author = {David Bergeron and Leila Sellami and Stéphane Poulin and Louis Verret and Rémi W Bouchard and Robert Laforce},

doi = {10.1159/000511210},

issn = {1421-9824},

year  = {2020},

date = {2020-01-01},

journal = {Dement Geriatr Cogn Disord},

volume = {49},

number = {5},

pages = {518--525},

abstract = {INTRODUCTION: It is well known that some patients with Alz-heimer's disease (AD) have atypical, nonamnestic presentations. While logopenic aphasia and posterior cortical atrophy are well-characterized atypical variants of AD, the behavioral/dysexecutive variant remains a controversial entity, lacking consensus regarding its distinctive clinical and imaging features.nnMETHODS: We present a case series of 8 patients with biomarker confirmation of AD (cerebrospinal fluid [CSF] analysis or amyloid positron emission tomography [PET]) and a progressive frontal syndrome, defined as prominent behavioral and/or executive deficits at initial presentation. We characterize the cohort based on clinical features, cognitive performance in 4 domains (memory, visuospatial, executive, and language) as well as behavior on the Dépistage Cognitif de Québec (DCQ), and regional brain metabolism using 18F-fluorodeoxyglucose PET (FDG-PET). We compare these features with 8 age-matched patients diagnosed with the behavioral variant of frontotemporal dementia (bvFTD) and 37 patients with typical amnestic AD.nnRESULTS: Patients with the behavioral/dysexecutive variant of AD presented with early-onset (mean age: 59 years old) progressive executive and behavioral problems reminiscent of bvFTD, including disinhibition, loss of social conventions, and hyperorality. Patients scored higher on the Memory Index and lower on the Behavioral Index than patients with amnestic AD on the DCQ, yet they were indistinguishable from patients with bvFTD on each of the cognitive indices. Visual analysis of FDG-PET revealed half of patients with behavioral/dysexecutive AD presented with frontal hypometabolism suggestive of bvFTD and only 3/8 (37.5%) presented significant hypometabolism of the posterior cingulate cortex. Group-level analysis of FDG-PET data revealed that the most hypometabolic regions were the middle temporal, inferior temporal, and angular gyri in behavioral/dysexecutive AD and the inferior frontal gyrus, anterior cingulate cortex, caudate nucleus, and insula in bvFTD.nnCONCLUSION: The behavioral/dysexecutive variant of AD is a rare, atypical young-onset variant of AD defined clinically by early and prominent impairments in executive and behavioral domains. While behavioral/dysexecutive AD is hardly distinguishable from bvFTD using clinical and cognitive features alone, CSF biomarkers and temporoparietal hypometabolism help predict underlying pathology during life.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid33113530,

title = {Cognitive Profile of the Logopenic Variant of Primary Progressive Aphasia Using the Dépistage Cognitif de Québec},

author = {Sarah Montreuil and Elizabeth Poulin and David Bergeron and Leila Sellami and Louis Verret and Marie-Pierre Fortin and Stéphane Poulin and Joël Macoir and Carol Hudon and Rémi W Bouchard and Monica Lavoie and Robert Laforce},

doi = {10.1159/000510501},

issn = {1421-9824},

year  = {2020},

date = {2020-01-01},

journal = {Dement Geriatr Cogn Disord},

volume = {49},

number = {4},

pages = {410--417},

abstract = {BACKGROUND/AIMS: The logopenic variant of primary progressive aphasia (lvPPA) is characterized by impaired word-finding and sentence repetition with phonologic errors but spared motor speech and grammar and semantic knowledge. Although its language deficits have been well studied, the full spectrum of cognitive changes in the lvPPA remains to be defined. We aimed to explore the neurocognitive profile of the lvPPA using a newly developed cognitive screening tool for atypical dementias, the Dépistage Cognitif de Québec (DCQ).nnMETHODS: We compared 29 patients with lvPPA to 72 amnestic variant Alzheimer disease (aAD) to 438 healthy control (HC) participants. Performance on the 5 indexes of the DCQ (Memory, Visuospatial, Executive, Language and Behavioral) was compared between the 3 groups.nnRESULTS: Results showed a significantly lower performance for lvPPA participants in all neurocognitive domains, when compared to HC. When compared to aAD, lvPPA participants had significantly lower scores for language, executive, and visuospatial abilities, but not for memory and behavior.nnCONCLUSION: Altogether, these findings better define the neurocognitive changes of lvPPA.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}

@article{pmid27747317,

title = {Differences in Rate of Cognitive Decline and Caregiver Burden between Alzheimer's Disease and Vascular Dementia: a Retrospective Study},

author = {Marie-Hélène Pilon and Stéphane Poulin and Marie-Pierre Fortin and Michèle Houde and Louis Verret and Rémi W Bouchard and Robert Laforce},

year  = {2016},

date = {2016-03-01},

journal = {Neurology (ECronicon)},

volume = {2},

number = {6},

pages = {278--286},

abstract = {Few studies have explored the rate of cognitive decline and caregiver burden within the context of a specialized memory clinic. When this was done, the focus was largely on functional decline related to Alzheimer's disease (AD). Our goal was to compare the longitudinal decline of AD patients to those with Vascular Dementia (VaD) on Mini-Mental State Examination (MMSE). We further explored the differential impact on caregiver burden. We retrospectively studied 237 charts from patients seen at our Memory Clinic between 2006 and 2012. The data was collected over 17 years. Cohorts were formed by excluding conditions other than AD and VaD, and including patients who had been assessed at least twice with the MMSE (AD: n = 83; mean age: 67.7 yo; VaD: n = 32; mean age: 73.3yo). A small group of 36 caregivers was surveyed by phone to explore caregiver burden. Results indicated that the natural history of MMSE changes in AD patients differed significantly from that of patients with VaD (F = 10.41, p<0.0014), with AD patients showing more cognitive decline over time. Sadness, stress/anxiety, fatigue, and sleep disorders were reported as the main preoccupations by caregivers and its impact was rated as 'severe' in 50% of cases. Altogether, this study provides further insight into the natural history of cognitive decline in AD and VaD. Future studies should explore the progression of dementing disorders in larger cohorts using prospective methodological designs.},

keywords = {},

pubstate = {published},

tppubtype = {article}

}